Analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00. The firm has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24.
About Genocea Biosciences
Featured Stories
- Five stocks we like better than Genocea Biosciences
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- AMD is Down 35%. Now is the Time to Buy the Dip
- What is an Earnings Surprise?
- Amazon Stands Tall: New Highs Are in Sight
- The 3 Best Fintech Stocks to Buy Now
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.